SecBot SecBot
PRESS-RELEASE ·Filed Aug 3, 2026

RGNX

REGENXBIO Inc.
NEUTRAL
Impact 1/10
Horizondays Processed3mo ago WireGlobeNewswire
Press release · Earnings

Drugs in focus

RGNX drug pipeline →

surabgene lomparvovec

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
If positive Phase 3 data in Q4 2026, regulatory filing likely 2027 with potential FDA approval 2028 for wet AMD (subretinal). Diabetic retinopathy program (NAAVIGATE) is Phase IIb/III and further out.
Next catalyst
None dated

What to watchWatch for topline Phase 3 data from ATMOSPHERE/ASCENT in Q4 2026, this is the single biggest binary event for RGNX. Interim ALTITUDE data at ASRS July 2026 provides a near-term sentiment check. The $100M AbbVie milestone extends cash runway into late 2027, reducing near-term dilution risk.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.96
T+0 close · Aug 3, 2026 · via day close
Latest settled
−33.84%
T+60 · $6.59
Vs SPY
−35.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $9.96entry
  2. T+1 · 4mo ago +3.41%α +1.61% · $10.30
  3. T+5 · 3mo ago +4.62%α +2.59% · $10.42
  4. T+20 · 3mo ago −4.62%α −5.86% · $9.50
  5. T+60 · 21d ago −33.84%α −35.62% · $6.59
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

REGENXBIO Inc. announced it will host a conference call on August 6 to discuss its Q2 2026 results.

Key Facts

  • REGENXBIO Inc. announced it will host a conference call on August 6 to discuss its Q2 2026 results.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302840354

Track record

15 reports on RGNX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
  2. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
  3. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
  4. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
  5. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
  6. Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
  7. Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
  8. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
  9. Aug 3, 202615w ago Press Release Neutral 1/10 Viewing Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
  10. Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026